Long-Term Efficacy and Safety of JAK Inhibitors in Atopic Dermatitis

Video content above is prompted by the following:

• How do the long-term efficacy data compare with other treatment options for AD? What are your thoughts on sustained results achieved with monotherapy?
• Abrocitinib
• 96-week data showed more patients were able to achieve IGA 0/1 and EASI-75, 90, and 100 with abrocitinib monotherapy than those who added topical therapy.
• Upadacitinib
• The 188-week data showed that a high proportion of patients on upadacitinib monotherapy were able to achieve EASI-75 (86.3% and 89%) and vIGA-AD 0/1 (59.5% and 61.8%).
• How has the long-term safety of abrocitinib and upadacitinib affected your comfort level of keeping patients on JAK inhibitors long-term to treat AD? Are there certain patient types that might not be appropriate for long-term use?
• Abrocitinib 4-year safety
• Incidence rates for malignancy, major adverse cardiac events (MACE), and venous thromboembolism (VTE) remain low but were numerically higher for patients older than 65 years.
• Adverse event rates are generally consistent between 100 mg, 200 mg, and variable dose cohorts, with a dose-dependent response for herpes zoster and herpes simplex infections.
• Upadacitinib 6-year safety
• Incidence rates for malignancy, MACE, and VTE remain low (≤0.5 patients per 100 patient-years) and generally reflect the background observations of these events in the overall AD population.
• Adverse event rates are generally consistent between 15-mg and 30-mg doses (slightly higher herpes zoster rates with 30-mg dose